Analytical Data
-
Gene name
ATN1
- Application
-
Alternative Names
B37; DRPLA; NOD; Dentatorubral Pallidoluysian Atrophy
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P54259
-
Expression Region
Asp879~Leu1190
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ATN1, or ataxin-1, is a protein associated with the pathogenesis of spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive incoordination and motor dysfunction. Mutations in the ATN1 gene lead to an expansion of CAG repeats, resulting in a polyglutamine (polyQ) expansion in the protein. This expansion is thought to cause aberrant protein folding, aggregation, and disruption of cellular functions, particularly in neurons. The study of recombinant ATN1 proteins is crucial for understanding the molecular mechanisms underlying SCA1 and for exploring potential therapeutic strategies. Research in this area has focused on the characterization of the structural and functional properties of ATN1, investigating how the polyQ tract influences protein behavior and interactions with other cellular components. Additionally, studies utilize recombinant ATN1 to assess toxicity mechanisms in cellular models, aiming to identify pathways that could be targeted to alleviate symptoms or slow disease progression. Overall, the research on ATN1 recombinant proteins not only enhances our understanding of SCA1 but also holds promise for advancing therapeutic developments for related neurodegenerative disorders.
